Metformin extended release mechanism of action

Pro Research Analysisby

Searched over 200M research papers

Analyzed relevant papers

Metformin Extended Release: Mechanism of Action Keywords

Gut-Based Mechanism and Lower Bowel Delivery

Metformin extended-release (XR) formulations are designed to release the drug slowly, often targeting the lower bowel. This approach leverages the gut-based mechanisms of metformin, which are now recognized as central to its glucose-lowering effect. Studies show that even with lower plasma levels, metformin XR and delayed-release forms can significantly reduce fasting plasma glucose, supporting the idea that much of metformin’s action occurs in the gut rather than through systemic circulation .

Mitochondrial Effects and Inhibition of Hepatic Gluconeogenesis

A key molecular mechanism of metformin, including its extended-release form, is the inhibition of mitochondrial respiratory-chain complex 1. This action reduces the liver’s production of glucose (hepatic gluconeogenesis), which is a major contributor to high blood sugar in type 2 diabetes. By targeting mitochondria, metformin also decreases the generation of reactive oxygen species and may protect cells from oxidative stress Rena2013Vial2019.

AMPK-Dependent and Independent Pathways

Metformin’s action was long thought to be mainly through activation of AMP-activated protein kinase (AMPK), which helps regulate energy balance and glucose metabolism. However, recent research suggests that metformin also works through AMPK-independent pathways, particularly by directly affecting mitochondrial function and possibly influencing hormone signaling, such as glucagon Rena2013Vial2019.

Gastroretentive and Mucoadhesive Drug Delivery

Some extended-release formulations use gastroretentive and mucoadhesive technologies to keep the tablet in the stomach for longer periods. This allows for a more gradual and sustained release of metformin, improving its absorption in the upper gastrointestinal tract and mimicking the natural, slow absorption that enhances its gut-based effects .

Clinical Implications and Tolerability

Metformin XR is recommended as a first-line treatment for type 2 diabetes due to its efficacy, safety, and tolerability. Extended-release formulations are often better tolerated than immediate-release forms, with fewer gastrointestinal side effects, making them suitable for long-term use .

Conclusion

Metformin extended-release works primarily by targeting the gut and inhibiting glucose production in the liver through mitochondrial mechanisms. Its action involves both AMPK-dependent and independent pathways, with extended-release formulations designed to optimize these effects while minimizing side effects. This makes metformin XR a cornerstone in the management of type 2 diabetes Buse2015Satterwhite2021Rena2013+2 MORE.

Sources and full results

Most relevant research papers on this topic

The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies

Metformin's primary glucose-lowering effect is predominantly mediated through the gut, not the circulation, with gut-restricted Met DR providing lower plasma exposure and better glycemic control in type 2 diabetes patients.

RCTVery Rigorous Journal

2015·

303citations

·J. Buse et al.

Diabetes Care·

DOI

Metformin Extended-Release Oral Solution

Metformin extended-release oral suspension (Riomet ER) is an FDA-approved treatment for type 2 diabetes, recommended as the preferred initial pharmacological agent by the American Diabetes Association.

2021·

5citations

·L. E. Satterwhite

Clinical Diabetes·

DOI

Molecular mechanism of action of metformin: old or new insights?

Recent research challenges the notion that AMPK mediates metformin's anti-hyperglycemic action, highlighting AMPK-independent effects and potential new targets for second-generation diabetes drugs.

Rigorous Journal

2013·

464citations

·G. Rena et al.

Diabetologia·

DOI

Role of Mitochondria in the Mechanism(s) of Action of Metformin

Metformin's mechanism of action involves modulating mitochondrial bioenergetics, potentially inhibiting cancer cell growth and proliferation.

2019·

260citations

·G. Vial et al.

Frontiers in Endocrinology·

DOI

Gastroretentive extended release of metformin from methacrylamide-g-gellan and tamarind seed gum composite matrix.

The optimized gastroretentive extended release tablet of metformin based on polymethacrylamide-g-gellan and tamarind seed gum composite matrix showed excellent buoyancy, significant mucoadhesion, and drug release over a 10 hour period with a non-Fickian transport based mechanism.

In Vitro Exp.

2016·

44citations

·R. Priyadarshini et al.

Carbohydrate polymers·

DOI

Metformin: update on mechanisms of action and repurposing potential

Metformin's complex mechanisms of action involve multiple organs and may be repurposed for treating cancer, age-related diseases, inflammatory diseases, and COVID-19.

2023·

569citations

·M. Foretz et al.

Nature Reviews. Endocrinology·

DOI

The mechanisms of action of metformin

Metformin improves glucose metabolism and diabetes-related complications through multiple mechanisms, including reducing hepatic glucose production and a key role for the gut.

Literature ReviewRigorous Journal

2017·

1993citations

·G. Rena et al.

Diabetologia·

DOI

Cellular and Molecular Mechanisms of Metformin Action

Metformin's glucose-lowering effect in type 2 diabetes is primarily due to its inhibition of hepatic gluconeogenesis, with recent studies suggesting a redox-dependent mechanism at clinically relevant concentrations.

Literature Review

2020·

620citations

·Traci E LaMoia et al.

Endocrine Reviews·

DOI

Metformin: from mechanisms of action to therapies.

Metformin's mechanism of action centers on energy metabolism, potentially impacting cardiovascular diseases and cancer, with AMPK-dependent and -independent mechanisms underlying its actions.

Very Rigorous Journal

2014·

1370citations

·M. Foretz et al.

Cell metabolism·

DOI

Extended-release metformin improves cognitive impairment in frail older women with hypertension and diabetes: preliminary results from the LEOPARDESS Study

Extended-release metformin improves cognitive impairment in frail older women with diabetes and hypertension, for the first time.

2023·

23citations

·P. Mone et al.

Cardiovascular Diabetology·

DOI

Try another search

molecular biologist role

cholesterol levels by age

analytical chemistry

probiotics and cultural dietary practices

smallest planet in the solar system

iron deficiency in men